Bet­ting ear­ly on an AI niche, RA Cap­i­tal seeds a young founder's quest to un­lock 'Holy Grail' tar­gets

Ar­ti­fi­cial in­tel­li­gence, with its grandiose claims and sweep­ing promis­es to rev­o­lu­tion­ize drug dis­cov­ery, may seem om­nipresent in bio­phar­ma now. But Vir­ginia Burg­er and RA Cap­i­tal be­lieve there are nich­es it has yet to touch.

Af­ter tak­ing up res­i­den­cy at the star-stud­ded Boston ac­cel­er­a­tor Petri, Burg­er’s start­up — named New Equi­lib­ri­um Bio­sciences — has scored $10 mil­lion in seed cash from the VC firm to prove that by reach­ing in­to those cor­ners, they could un­cov­er drugs against “Holy Grail” tar­gets in every­thing from can­cer to neu­rode­gen­er­a­tive dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER